A5087999170- Chronic Obstructive Pulmonary Disease (COPD) Research
- Asthma and respiratory diseases
- Respiratory Support and Mechanisms
- Respiratory and Cough-Related Research
- Inhalation and Respiratory Drug Delivery
- Pulmonary Hypertension Research and Treatments
- Pediatric health and respiratory diseases
- Neonatal Respiratory Health Research
- Cardiovascular and exercise physiology
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cardiovascular Function and Risk Factors
- Health, Environment, Cognitive Aging
- Cystic Fibrosis Research Advances
- Nutrition, Genetics, and Disease
- Delphi Technique in Research
- Tuberous Sclerosis Complex Research
- Chronic Disease Management Strategies
- Physical Activity and Health
- IL-33, ST2, and ILC Pathways
- Eosinophilic Esophagitis
- Obstructive Sleep Apnea Research
- Allergic Rhinitis and Sensitization
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Lung Cancer Diagnosis and Treatment
- Balance, Gait, and Falls Prevention
German Center for Lung Research
2016-2025
LungenClinic Grosshansdorf
2016-2025
Velocity Clinical Research (United States)
2025
University of Lübeck
2011-2023
University Hospital Schleswig-Holstein
2023
Ludwig-Maximilians-Universität München
2020
Boehringer Ingelheim (United Kingdom)
2015
Boehringer Ingelheim (Germany)
2015
Maastricht University Medical Centre
2015
Universitat de Barcelona
2015
The present study aimed to measure physical activity in patients with chronic obstructive pulmonary disease (COPD) to: 1) identify the stage at which becomes limited; 2) investigate relationship of clinical characteristics activity; 3) evaluate predictive power identifying very inactive patients; and 4) analyse reliability measurements. In total, 163 COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) I–IV; BODE (body mass index, airway obstruction, dyspnoea, exercise...
Treatment with inhaled glucocorticoids in combination long-acting bronchodilators is recommended patients frequent exacerbations of severe chronic obstructive pulmonary disease (COPD). However, the benefit addition to two has not been fully explored.In this 12-month, double-blind, parallel-group study, 2485 a history exacerbation COPD received triple therapy consisting tiotropium (at dose 18 μg once daily), salmeterol (50 twice and glucocorticoid fluticasone propionate (500 daily) during...
This European Respiratory Society (ERS) statement provides a comprehensive overview on physical activity in patients with chronic obstructive pulmonary disease (COPD). A multidisciplinary Task Force of experts representing the ERS Scientific Group 01.02 “Rehabilitation and Chronic Care” determined overall scope this through consensus. Focused literature reviews were conducted key topic areas final content Statement was agreed upon by all members. The current knowledge regarding COPD is...
Physical activity is reduced in patients with chronic obstructive pulmonary disease (COPD). COPD has a systemic component that includes significant extrapulmonary effects may contribute to its severity individual patients.To investigate the association of and comorbidities physical COPD.In cross-sectional study, 170 outpatients (GOLD [Global Initiative for Chronic Obstructive Lung Disease] stages I-IV; BODE [body mass index, airway obstruction, dyspnea, exercise capacity] score 0-10)...
Efficacy and safety of tiotropium+olodaterol fixed-dose combination (FDC) compared with the mono-components was evaluated in patients moderate to very severe chronic obstructive pulmonary disease (COPD) two replicate, randomised, double-blind, parallel-group, multicentre, phase III trials. Patients received FDC 2.5/5 μg or 5/5 μg, tiotropium 2.5 5 olodaterol delivered once-daily via Respimat inhaler over 52 weeks. Primary end points were forced expiratory volume 1 s (FEV1) area under curve...
Little is known about the role of physical activity in course chronic obstructive pulmonary disease (COPD).To assess changes COPD relation to severity stages and other components, evaluate longitudinal association between sustained inactivity progression.In this prospective cohort study, we measured (multisensory armband), airflow obstruction (FEV1), health status (St. George's Respiratory Questionnaire), exercise capacity (6-min-walk distance [6MWD]), muscle mass (fat-free [FFM]), systemic...
An antagonist (MK-7123) of the cytokine receptor CXCR2 reduces neutrophil chemotaxis and thus may alleviate airway inflammation in chronic obstructive pulmonary disease (COPD).To assess efficacy, safety, tolerability three dose levels MK-7123, compared with placebo, patients moderate to severe COPD.This 6-month, double-blind study randomized COPD (already on standard therapy) daily MK-7123 at 10, 30, or 50 mg placebo. The primary endpoint was change from baseline post-bronchodilator FEV1.A...
SCH527123 is a novel, selective CXC chemokine receptor 2 antagonist that inhibits neutrophil activation and modulates trafficking in animal models, characteristics may be beneficial the treatment of conditions with unbalanced pulmonary neutrophilia, such as chronic obstructive disease. The purpose this proof-of-principle study was to determine whether ozone-induced recruitment healthy humans. In randomised, double-blind, placebo-controlled, three-way crossover study, oral (50 mg once daily,...
This document is a revision of the guideline for diagnosis and treatment COPD that replaces version from 2007. A multitude recent reports regarding risk factors, diagnosis, assessment, prevention pharmacological as well non-pharmacological options made major mandatory. The new based on GOLD taking into account specifics in Germany Austria.Das vorliegende Dokument ist eine Neufassung und Aktualisierung der Leitlinie zur Diagnostik Therapie von Patienten mit COPD, die bisherige Version aus dem...
BackgroundThe German COPD cohort study COSYCONET ("COPD and SYstemic consequences-COmorbidities NETwork") investigates the interaction of lung disease, comorbidities systemic inflammation. Recruitment took place from 2010 to 2013 in 31 centers. In addition baseline visit, follow-up visits are scheduled at 6, 18, 36 54 months after baseline. The also comprises a biobank, image bank, includes health economic data. Here we describe design present data our cohort.MethodsInclusion criteria were...
Chronic Obstructive Pulmonary Disease (COPD) influences different aspects of patient's health-related quality life (HRQL). While disease-specific HRQL instruments focus on symptoms and functional impairments, generic cover a broader view health. This study compares the EQ-5D-3 L two questionnaires (St.-George's Respiratory Questionnaire (SGRQ-C), COPD Assessment Test (CAT)) in comprehensive spectrum disease grades with particular attention comorbidities assesses discriminative abilities...
Rationale: Knowledge about the prevalence of objectively assessed peripheral artery disease (PAD) and its clinical relevance in patients with chronic obstructive pulmonary (COPD) is scarce.Objectives: We aimed to: (1) assess PAD COPD compared distinct control groups; (2) study association between functional capacity as well health status.Methods: The ankle–brachial index was used to diagnose (ankle–brachial ≤ 0.9). 6-minute-walk distance, status (St. George’s Respiratory Questionnaire),...
Physical activity (PA) is of key importance for health among healthy persons and individuals with chronic obstructive pulmonary disease (COPD). PA has multiple dimensions that can be assessed quantified objectively using monitors. Moreover, as shown in the published literature, variable methodologies have been used to date quantify COPD, precluding clear comparisons outcomes across studies. The present paper aims provide a summary available literature rationale behind measured proposes...
Rationale In adults, personalised asthma treatment targets patients with type 2 (T2)-high and eosinophilic phenotypes. It is unclear whether such classification achievable in children. Objectives To define T2-high easily accessible biomarkers compare resulting phenotypes across all ages. Methods the multicentre clinical All Age Asthma Cohort (ALLIANCE), 1125 participants (n=776 asthmatics, n=349 controls) were recruited followed for years (1 year adults). Extensive characterisation...
Background The development of optimal strategies to treat impaired mobility related ageing and chronic disease requires better ways detect measure it. Digital health technology, including body worn sensors, has the potential directly accurately capture real-world mobility. Mobilise-D consists 34 partners from 13 countries who are working together jointly develop implement a digital assessment solution demonstrate that outcomes have provide better, safer, quicker way assess, monitor, predict...